Talaris Therapeutics Overview
- Year Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
4
- Latest Deal Type
-
M&A
Talaris Therapeutics General Information
Description
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders.
Contact Information
Website
www.talaristx.comCorporate Office
- 300 East Market Street
- Suite 350
- Louisville, KY 40202
- United States
Corporate Office
- 300 East Market Street
- Suite 350
- Louisville, KY 40202
- United States
Talaris Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Merger/Acquisition | 19-Oct-2023 | Completed | Generating Revenue | |||
| 8. IPO | 07-May-2021 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series B) | 30-Sep-2020 | Completed | Clinical Trials - Phase 3 | |||
| 6. Later Stage VC (Series A) | 18-Apr-2019 | Completed | Clinical Trials - Phase 3 | |||
| 5. Grant | 01-Jan-2012 | Completed | Clinical Trials - Phase 3 | |||
| 4. Grant | 01-Jan-2011 | Completed | Clinical Trials - Phase 3 | |||
| 3. Grant | 01-Jan-2008 | Completed | Clinical Trials - Phase 3 | |||
| 2. Grant | 01-Jan-2005 | $1.61M | Completed | Clinical Trials - Phase 3 | ||
| 1. Grant | 01-Jan-2004 | $441K | Completed | Clinical Trials - Phase 3 |
Talaris Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | 40,000,000 | $0.000100 | $1 | $1 | 1x | $1 | 20.73% |
Talaris Therapeutics Comparisons
Industry
Financing
Details
Talaris Therapeutics Competitors (30)
One of Talaris Therapeutics’s 30 competitors is Rein Therapeutics, a Formerly VC-backed company based in Austin, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Tetherex Pharmaceuticals | Venture Capital-Backed | Oklahoma City, OK | ||||
| Pharmacyclics | Venture Capital-Backed | San Francisco, CA | ||||
| OrphoMed | Venture Capital-Backed | San Francisco, CA | ||||
| Verastem | Formerly VC-backed | Needham, MA |
Talaris Therapeutics Signals
Talaris Therapeutics Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| BlackRock | Asset Manager | Minority | ||
| Citadel Enterprise Americas | Hedge Fund | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| Eventide Asset Management | Venture Capital | Minority |
Talaris Therapeutics Acquisitions (1)
Talaris Therapeutics’s most recent deal was a Reverse Merger with Tourmaline Bio. The deal was made on 19-Oct-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Tourmaline Bio | 19-Oct-2023 | Reverse Merger | Drug Discovery |
Talaris Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
34.39 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Talaris Therapeutics FAQs
-
When was Talaris Therapeutics founded?
Talaris Therapeutics was founded in 2002.
-
Where is Talaris Therapeutics headquartered?
Talaris Therapeutics is headquartered in Louisville, KY.
-
What is the size of Talaris Therapeutics?
Talaris Therapeutics has 4 total employees.
-
What industry is Talaris Therapeutics in?
Talaris Therapeutics’s primary industry is Biotechnology.
-
Is Talaris Therapeutics a private or public company?
Talaris Therapeutics is a Private company.
-
What is Talaris Therapeutics’s current revenue?
The current revenue for Talaris Therapeutics is .
-
How much funding has Talaris Therapeutics raised over time?
Talaris Therapeutics has raised $365M.
-
Who are Talaris Therapeutics’s investors?
Aisling Capital, BlackRock, Citadel Enterprise Americas, Cormorant Asset Management, and Eventide Asset Management are 5 of 13 investors who have invested in Talaris Therapeutics.
-
Who are Talaris Therapeutics’s competitors?
Rein Therapeutics, Tetherex Pharmaceuticals, Pharmacyclics, OrphoMed, and Verastem are some of the 30 competitors of Talaris Therapeutics.
-
When was Talaris Therapeutics acquired?
Talaris Therapeutics was acquired on 19-Oct-2023.
-
Who acquired Talaris Therapeutics?
Talaris Therapeutics was acquired by Tourmaline Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process